EVO ICL and Nearsightedness
The frustration of dealing with your glasses or corrective lenses day-in and day-out very seldom outweighs the frustration caused by not being able to see without them. Fortunately, there’s EVO ICL (EVO), a long-lasting, minimally invasive solution to your vision woes. Find out how EVO ICL is specifically designed for patients dealing with nearsightedness.
Nearsightedness, or myopia, is a vision condition in which people can see close objects clearly, but objects farther away appear blurred. People with myopia may have difficulty clearly seeing things at a distance, such as a movie or TV screen or the whiteboard in school.
Myopia affects nearly 30 percent of the U.S. population. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop it over time.
Even though the risk of developing myopia may be inherited, a person who overly uses his or her eyes may increase their chances. Individuals who spend considerable time reading, working at a computer, or doing other intense close visual work may be at a greater risk of developing myopia.
How Is Nearsightedness/Myopia Corrected?
People with myopia have several options available to regain clear vision. These include:
- Contact Lenses
- Ortho-k or CRT
- Laser Procedures (LASIK, PRK)
- Refractive Surgery Procedures
- Vision Therapy (Only for people with stress-related myopia)
LASIK for Nearsightedness/Myopia
Laser procedures such as LASIK are one of the possible treatment options for myopia in adults. A laser beam of light reshapes the cornea by removing a small amount of eye tissue. The amount of myopia that LASIK can correct is limited by the amount of corneal tissue that can be safely removed.
EVO ICL for Nearsightedness/Myopia
Many patients are finding the EVO ICL to be a great alternative to refractive surgeries including LASIK, photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eye glasses.
With its ability to correct moderate to high nearsightedness (-3.0 to –15.0 diopters (D)), and the reduction of nearsightedness in patients with up to -20 diopters (D), EVO ICL has a 99.4 percent satisfaction rate among patients who’ve had it performed.
The biggest benefit you notice after EVO ICL surgery is the permanent correction or reduction of your nearsightedness, allowing you to see clearly at long distances without eyeglasses or contact lenses or reduce your dependence upon them.
Start seeing the world clearly through your natural eyes. Find out if EVO ICL is right for you by scheduling a consultation with a doctor near you today.
Important Safety Information
The EVO Visian ICL Lens is intended for the correction of moderate to high nearsightedness. EVO Visian ICL and EVO Visian TICL surgery is intended to safely and effectively correct nearsightedness between -3.0 D to -15.0 D, the reduction in nearsightedness up to -20.0 D and treatment of astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before.
Implantation of the EVO Visian ICL is a surgical procedure, and as such, carries potentially serious risks. Please discuss the risks with your eye care professional. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts.
You should NOT have EVO Visian ICL surgery if:
- Your doctor determines that the shape of your eye is not an appropriate fit for the EVO Visian ICL
- You are pregnant or nursing
- You have moderate to severe damage to the optic nerve caused by increased pressure (glaucoma)
- You do not meet the minimum endothelial cell density for your age at the time of implantation as determined by your eye doctor
- Your vision is not stable as determined by your eye doctor
Before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. For additional information with potential benefits, risks and complications please visit DiscoverICL.com.
Select Your Region
¹Patient Survey, STAAR Surgical ICL Data Registry, 2018
²Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46.
³Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
⁴Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
5aLee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
5bParkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.
⁶Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
⁷Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53.
⁸Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
⁹Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.